Release Date: May 15, 2025
Expiration Date: May 15, 2026
Activity Overview
Providing early diagnosis and patient-centered treatment for neurotrophic keratitis (NK)—a condition that results from disrupted corneal innervation—can pose challenges. Management of NK requires the identification of symptoms that may be subtle and an understanding of the factors underlying each patient’s disease. In this program, a panel of experts provides key insights into making a prompt NK diagnosis and developing a treatment plan based on patient-specific factors.
This educational activity is an archive of the live symposium held on March 29, 2025.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in managing patients with NK.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate appropriate evaluation tools to ensure an early and accurate diagnosis of NK
- Evaluate current and emerging treatment strategies for NK
- Develop individualized management plans for patients with NK
Melissa Barnett, OD, FAAO, FSLS, FBCLA
Director of Optometry
University of California, Davis
Davis, CA
Disclosure: Speaker’s Bureau: ABB, AbbVie, Alcon, Bausch + Lomb, BCLA, CooperVision, Dompé US, Sjögren’s Foundation, STAPLE Program, Tarsus Pharmaceuticals, Théa Pharma; Other: ABB, AbbVie, Alcon, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Cloudbreak Pharma, CooperVision, Dompé US, Epion Therapeutics, GP Lens Institute, Glaukos, Johnson & Johnson Vision, OCuSOFT, Orasis Pharmaceuticals, Percept, ScienceBased Health, Sjögren’s Foundation, Tarsus Pharmaceuticals, Théa; Pharma Global Ambassador: BCLA; Podcast: National Keratoconus Foundation.
Cecelia Koetting, OD, FAAO, DipABO
Clinical Instructor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO
Disclosure: Grant Support: KALA BIO, Ocular Therapeutix, Viatris, Tarsus Pharmaceuticals; Consultant: Alcon, Aldeyra Therapeutics, AbbVie, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder Healthcare, Dompé US, Glaukos, Myze, Orasis Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Théa Pharma, Topcon Healthcare, Twenty/Twenty, Verséa Ophthalmics, Visus Therapeutics; Speaker’s bureau: Alcon, Bausch + Lomb, Dompé US, Glaukos, Harrow, Viatris, Sight Sciences.
Quan Đông Nguyễn, MD, MSc
Professor of Ophthalmology
Byers Eye Institute, Stanford University School of Medicine
Stanford, CA
Disclosure: Research Support: Active Biotech, Genentech, Oculis, Priovant, Regeneron; Advisory Boards: Kriya, Oculis, Priovant, Regeneron.
Jennifer Li, MD
Professor, MED: Eye Center
UC Davis Health System Eye Center
The following individuals have no relevant financial relationships with ineligible companies to disclose: Jennifer Li, MD, and the staff of Physicians’ Education Resource, LLC.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
